β-Carboline-benzoquinolizidine alkaloid deoxytubulosine inhibits thymidylate synthase activity in leukemic leukocytes from patients with chronic myeloblastic leukemia and acute lymphoblastic leukemia
作者:
K Narasimha Rao,
RK Bhattacharya,
SR Venkatachalam,
期刊:
Anti-Cancer Drugs
(OVID Available online 1998)
卷期:
Volume 9,
issue 8
页码: 727-732
ISSN:0959-4973
年代: 1998
出版商: OVID
关键词: Acute lymphoblastic leukemia;antitumor compound;chronic myeloblastic leukemia;deoxytubulosine;inhibition;thymidylate synthase
数据来源: OVID
摘要:
Precursor 2'-deoxythymidine 5'-monophosphate for DNA biosynthesis Is supplied by thymidylate synthase (TS) (EC 2.1.1.45) through a denovopathway and the enzyme levels are elevated in malignancy. TS is therefore a key target for cancer chemotherapy. Human leukocyte TS levels in patients with chronic myeloblastic leukemia (CML) and acute lymphoblastic leukemia (ALL) are highly elevated (66- and 33- fold, respectively) compared to the low baseline activity of normal healthy controls. Preliminary screening tests for the antitumor activity of theβ-carboline-benzoquinolizidine alkaloid deoxytubulosine (DTB) (isolated from the Indian medicinal plantAlanguim lamarcktii) were performed employing Invitroinhibition studies on the leukemic leukocyte TS as the probe enzyme. Enzyme activity of the leukemic leukocytes was potently inhibited by DTB (IC50=50µM) In both CML and ALL. The emetine alkaloid DTB was assessed for its biochemical and biological evaluation for the first time as a potential antileukemic agent.
点击下载:
PDF
(406KB)
返 回